Pharmacokinetics of Daunorubicin in Young Patients With Cancer

Not Recruiting

Trial ID: NCT00673257

Purpose

This laboratory study is looking at the pharmacokinetics of daunorubicin in young patients with cancer. Collecting and storing samples of blood from patients with cancer to study in the laboratory may help doctors learn more about how patients respond to treatment with certain chemotherapy drugs.

Official Title

Pharmacokinetics of Daunomycin in Children

Stanford Investigator(s)

Eligibility

DISEASE CHARACTERISTICS:

* Diagnosis of any malignancy
* Must be receiving a chemotherapy regimen that includes daunorubicin hydrochloride administered as an infusion of any duration for \< 24 hours on either a 1- or a 2-day schedule, including bolus and all short infusion schedules

PATIENT CHARACTERISTICS:

* Not pregnant or nursing
* No significant uncontrolled systemic illness
* Large implanted prostheses allowed (should not undergo dual energy x-ray absorptiometry scan)

PRIOR CONCURRENT THERAPY:

* See Disease Characteristics

Intervention(s):

other: pharmacological study

procedure: dual x-ray absorptimetry

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Peds Hem/Onc CRAs
650-723-5535

New Trial Alerts